

Application No. 09/455,542
Attorney Docket No. 045112-0041

1. A composition for the treatment of cancer, said composition comprising, a pharmaceutically acceptable carrier; and
 - at least one plant essential oil compound selected from the group consisting of benzyl alcohol, cinnamic alcohol, cinnamic aldehyde, α -terpineol, carvacrol, citronellal, p-cymene, eucalyptol (cineole), eugenol, iso-eugenol, guaiacol, limonene, methyl salicylate, α -phellandrene, thymol, and trans-anethole, said composition having a pharmaceutically effective amount of the plant essential oil compound selected on a basis of therapeutic treatment for cancer.
4. The composition of claim 1, wherein the cancer is breast cancer.
5. The composition of claim 1, wherein the compound is eugenol.

REMARKS

Claims 1, 4 and 5 are pending in the application. Claims 6-13 are canceled without prejudice to, or disclaimer of, the subject matter they contain. Applicants respectfully retain the right to file continuing applications. Claims 1, 4 and 5 are amended to encompass infringing subject matter. No new matter is added into the application.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned, "Version With Markings To Show Changes Made."

Applicants respectfully submit that entry of the above claim amendments is proper under 37 C.F.R. § 1.116 because the amendments: (a) place the application in condition for allowance (for the reasons discussed herein); (b) do not raise any new issues requiring further search and/or consideration (since the amendments amplify issues previously discussed throughout the prosecution); (c) do not present any additional claims without canceling a corresponding number of finally rejected claims; and (d) place the application in better form for appeal. Thus, entry of the foregoing amendments, reconsideration and reexamination of the claimed subject matter are respectfully requested.

The Rejections Under 35 U.S.C. §102(b)

Claims 1-5 are rejected under 35 U.S.C. §102(b) as allegedly being anticipated by Ref U (Kim et al., *Antianaphylactic Properties of Eugenol*, 36(6) Pharmacological Research, 475-480 (1997)), Ref V (Oita et al., 1985:427328), Ref W (Caplus 1991:115063), or REF X (Luc et al.,